Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2016 1
2017 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
HLA-DRalpha1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.
Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA. Meza-Romero R, et al. J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28. J Immunol. 2014. PMID: 24683185 Free PMC article.
CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immune-mediated diseases as part of the macrophage migration inhibitory factor (MIF) binding complex. ...We found that DRalpha1 directly inhibit
CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immune-medi
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, Offner H, Bucala R, Vandenbark AA. Benedek G, et al. Eur J Immunol. 2013 May;43(5):1309-21. doi: 10.1002/eji.201243162. Epub 2013 Apr 10. Eur J Immunol. 2013. PMID: 23576302 Free PMC article.
Here, we demonstrate for the first time that partial MHC class II constructs comprised of linked beta1alpha1 domains with covalently attached antigenic peptides (also referred to as recombinant T-cell receptor ligands - RTLs) can inhibit MIF activity by not o …
Here, we demonstrate for the first time that partial MHC class II constructs comprised of linked beta1alpha1 domains with covalently …
A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, Buenafe AC, Dahan R, Reiter Y, Mooney JL, Offner H, Burrows GG. Vandenbark AA, et al. J Autoimmun. 2013 Feb;40:96-110. doi: 10.1016/j.jaut.2012.08.004. Epub 2012 Sep 29. J Autoimmun. 2013. PMID: 23026773 Free PMC article.
Binding of RTL constructs with CD74 involved a previously unrecognized MHC class II-alpha1/CD74 interaction that inhibited CD74 expression, blocked activity of its ligand, macrophage migration inhibitory factor, and reduced EAE severity. …
Binding of RTL constructs with CD74 involved a previously unrecognized MHC class II-alpha1/CD74 interaction that inhibi …
DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.
Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, Liu H, Meza-Romero R, Vandenbark AA, Offner H, Gao Y. Wang J, et al. Transl Stroke Res. 2017 Jun;8(3):284-293. doi: 10.1007/s12975-016-0514-2. Epub 2016 Dec 17. Transl Stroke Res. 2017. PMID: 27988839 Free PMC article.
The human leukocyte antigen-DRalpha1 domain linked to MOG-35-55 peptide (DRalpha1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage …
The human leukocyte antigen-DRalpha1 domain linked to MOG-35-55 peptide (DRalpha1-MOG-35-55) is a partial major histocompatibility complex ( …
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine.
Loftis JM, Ramani S, Firsick EJ, Hudson R, Le-Cook A, Murnane KS, Vandenbark A, Shirley RL. Loftis JM, et al. Front Psychiatry. 2023 Nov 9;14:1259041. doi: 10.3389/fpsyt.2023.1259041. eCollection 2023. Front Psychiatry. 2023. PMID: 38025429 Free PMC article.
INTRODUCTION: Currently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, and adverse neuropsychiatric effects. We have shown that partial (p)MHC class II constructs (i.e., Recombinant T-cell receptor …
INTRODUCTION: Currently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, a …
A novel HLA-DRalpha1-MOG-35-55 construct treats experimental stroke.
Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H. Benedek G, et al. Metab Brain Dis. 2014 Mar;29(1):37-45. doi: 10.1007/s11011-013-9440-0. Metab Brain Dis. 2014. PMID: 24122483 Free PMC article.
Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. ...The novel DRalpha1-MOG-35-55 construct is highly therapeutic in e …
Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of …